Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints / S. Percy Ivy, Charles A. Kunos, Fernanda I. Arnaldez, Elise C. Kohn
ABSTRACT Introduction : Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. Areas covered : In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. Expert opinion : Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 28(2019), 9, Seite 771-785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ivy, S. Percy [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
ATM |
|---|
| Umfang: |
1 Online-Ressource (15 p) |
|---|
| doi: |
10.1080/13543784.2019.1657403 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011199954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011199954 | ||
| 003 | DE-627 | ||
| 005 | 20230720210237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2019.1657403 |2 doi | |
| 035 | |a (DE-627)KFL011199954 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/13543784.2019.1657403 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Ivy, S. Percy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints |c S. Percy Ivy, Charles A. Kunos, Fernanda I. Arnaldez, Elise C. Kohn |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (15 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction : Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. Areas covered : In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. Expert opinion : Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients | ||
| 653 | |a Homologous recombination | ||
| 653 | |a DNA repair deficiencies | ||
| 653 | |a BRCA wild type | ||
| 653 | |a BRCAwt | ||
| 653 | |a high grade serous ovarian cancer | ||
| 653 | |a biomarkers | ||
| 653 | |a PARP | ||
| 653 | |a DNA-PKcs | ||
| 653 | |a ATM | ||
| 653 | |a ATR | ||
| 653 | |a CHK1 | ||
| 653 | |a CHK2 | ||
| 653 | |a DNA damage repair | ||
| 653 | |a cell cycle | ||
| 653 | |a immune checkpoint inhibitors | ||
| 700 | 1 | |a Kunos, Charles A. |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaldez, Fernanda I. |e verfasserin |4 aut | |
| 700 | 1 | |a Kohn, Elise C. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 28(2019), 9, Seite 771-785 |h Online-Ressource |w (DE-627)KFL000006041 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2019 |g number:9 |g pages:771-785 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/13543784.2019.1657403 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2019 |e 9 |h 771-785 | ||